OBT-357

N/A

Report date: 2024/08/13 20:00:09

Base Information

Drug NameOBT-357
Drug Alias NameMEN-1112OX-001OX-357OBT-357
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 inhibitors
TargetsADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumItalyGermany +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMenariniOxford Biomedica
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMenarini Group
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A